The complement c3a receptor contributes to melanoma tumorigenesis by inhibiting neutrophil and CD4+ T cell responses

Journal of Immunology

Volumn 196, Issue 11, 2016, Pages 4783-4792

  Nabizadeh, Jamileh A ^a   Manthey, Helga D ^a   Steyn, Frederik J ^a,b   Chen, Weiyu ^a   Widiapradja, Alexander ^a   Akhir, Fazrena N ^a   Boyle, Glen M ^c   Taylor, Stephen M ^a   Woodruff, Trent M ^a   Rolfe, Barbara E ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3A RECEPTOR; COMPLEMENT RECEPTOR; UNCLASSIFIED DRUG; COMPLEMENT C3A RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; COLON CANCER; CONTROLLED STUDY; DRUG TARGETING; FEMALE; FLOW CYTOMETRY; GENE CONTROL; INFLAMMATION; MACROPHAGE; MELANOMA; MOUSE; MURINE MODEL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; DEFICIENCY; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; PATHOLOGY;

ANIMALS; CARCINOGENESIS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FEMALE; MELANOMA; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEUTROPHILS; RECEPTORS, COMPLEMENT;

EID: 84975127343     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1600210     Document Type: Article

References (51)

1. Eggermont, A. M., A. Spatz, and C. Robert. 2014. Cutaneous melanoma. Lancet 383: 816-827.
2. Ricklin, D., G. Hajishengallis, K. Yang, and J. D. Lambris. 2010. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11: 785-797.
3. Klos, A., E. Wende, K. J. Wareham, and P. N. Monk. 2013. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol. Rev. 65: 500-543.
4. Ajona, D., M. J. Pajares, L. Corrales, J. L. Perez-Gracia, J. Agorreta, M. D. Lozano, W. Torre, P. P. Massion, J. P. de-Torres, E. Jantus-Lewintre, et al. 2013. Investigation of complement activation product C4d as a diagnostic and prognostic biomarker for lung cancer. J. Natl. Cancer Inst. 105: 1385-1393.
5. Kim, D. Y., C. B. Martin, S. N. Lee, and B. K. Martin. 2005. Expression of complement protein C5a in a murine mammary cancer model: tumor regression by interference with the cell cycle. Cancer Immunol. Immunother. 54: 1026-1037.
6. Markiewski, M. M., R. A. DeAngelis, F. Benencia, S. K. Ricklin-Lichtsteiner, A. Koutoulaki, C. Gerard, G. Coukos, and J. D. Lambris. 2008. Modulation of the antitumor immune response by complement. Nat. Immunol. 9: 1225-1235.
7. Nunez-Cruz, S., P. A. Gimotty, M. W. Guerra, D. C. Connolly, Y. Q. Wu, R. A. DeAngelis, J. D. Lambris, G. Coukos, and N. Scholler. 2012. Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia 14: 994-1004.
8. Corrales, L., D. Ajona, S. Rafail, J. J. Lasarte, J. I. Riezu-Boj, J. D. Lambris, A. Rouzaut, M. J. Pajares, L. M. Montuenga, and R. Pio. 2012. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J. Immunol. 189: 4674-4683.
9. Gunn, L., C. Ding, M. Liu, Y. Ma, C. Qi, Y. Cai, X. Hu, D. Aggarwal, H. G. Zhang, and J. Yan. 2012. Opposing roles for complement component C5a in tumor progression and the tumor microenvironment. J. Immunol. 189: 2985-2994.
10. Maher, S. G., D. T. McDowell, B. C. Collins, C. Muldoon, W. M. Gallagher, and J. V. Reynolds. 2011. Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation. Ann. Surg. 254: 809-816, discussion 816-817.
11. Medina-Echeverz, J., F. Aranda, and P. Berraondo. 2014. Myeloid-derived cells are key targets of tumor immunotherapy. OncoImmunology 3: e28398.
12. Coulthard, L. G., and T. M. Woodruff. 2015. Is the complement activation product C3a a proinflammatory molecule Re-evaluating the evidence and the myth. J. Immunol. 194: 3542-3548.
13. Knight, D. A., S. F. Ngiow, M. Li, T. Parmenter, S. Mok, A. Cass, N. M. Haynes, K. Kinross, H. Yagita, R. C. Koya, et al. 2013. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J. Clin. Invest. 123: 1371-1381.
14. Rosenberg, S. A., P. Spiess, and R. Lafreniere. 1986. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318-1321.
15. Kildsgaard, J., T. J. Hollmann, K. W. Matthews, K. Bian, F. Murad, and R. A. Wetsel. 2000. Cutting edge: targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxinshock. J. Immunol. 165: 5406-5409.
16. March, D. R., L. M. Proctor, M. J. Stoermer, R. Sbaglia, G. Abbenante, R. C. Reid, T. M. Woodruff, K. Wadi, N. Paczkowski, J. D. Tyndall, et al. 2004. Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity. Mol. Pharmacol. 65: 868-879.
17. Daley, J. M., A. A. Thomay, M. D. Connolly, J. S. Reichner, and J. E. Albina. 2008. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J. Leukoc. Biol. 83: 64-70.
18. Mittler, R. S., T. S. Bailey, K. Klussman, M. D. Trailsmith, and M. K. Hoffmann. 1999. Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. J. Exp. Med. 190: 1535-1540.
19. Klos, A., A. J. Tenner, K. O. Johswich, R. R. Ager, E. S. Reis, and J. Köhl. 2009. The role of the anaphylatoxins in health and disease. Mol. Immunol. 46: 2753-2766.
20. Wu, M. C., F. H. Brennan, J. P. Lynch, S. Mantovani, S. Phipps, R. A. Wetsel, M. J. Ruitenberg, S. M. Taylor, and T. M. Woodruff. 2013. The receptor for complement component C3a mediates protection from intestinal ischemiareperfusion injuries by inhibiting neutrophil mobilization. Proc. Natl. Acad. Sci. USA 110: 9439-9444.
21. Fridlender, Z. G., J. Sun, S. Kim, V. Kapoor, G. Cheng, L. Ling, G. S. Worthen, and S. M. Albelda. 2009. Polarization of tumor-associated neutrophil phenotype by TGF-β: N1 versus N2 TAN. Cancer Cell 16: 183-194.
22. Piccard, H., R. J. Muschel, and G. Opdenakker. 2012. On the dual roles and polarized phenotypes of neutrophils in tumor development and progression. Crit. Rev. Oncol. Hematol. 82: 296-309.
23. Fleming, T. J., M. L. Fleming, and T. R. Malek. 1993. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. J. Immunol. 151: 2399-2408.
24. Manthey, H. D., T. M. Woodruff, S. M. Taylor, and P. N. Monk. 2009. Complement component 5a (C5a). Int. J. Biochem. Cell Biol. 41: 2114-2117.
25. Bonavita, E., S. Gentile, M. Rubino, V. Maina, R. Papait, P. Kunderfranco, C. Greco, F. Feruglio, M. Molgora, I. Laface, et al. 2015. PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell 160: 700-714.
26. Kim, B. S., S. G. Lee, S. Hwang, K. M. Park, K. H. Kim, C. S. Ahn, D. B. Moon, T. Y. Ha, G. W. Song, D. S. Kim, et al. 2007. Neurologic complications in adult living donor liver transplant recipients. Clin. Transplant. 21: 544-547.
27. Downs-Canner, S., D. Magge, R. Ravindranathan, M. E. O'Malley, L. Francis, Z. Liu, Z. Sheng Guo, N. Obermajer, and D. L. Bartlett. 2016. Complement inhibition: a novel form of immunotherapy for colon cancer. Ann. Surg. Oncol. 23: 655-662.
28. Woodruff, T. M., and A. J. Tenner. 2015. A commentary on: NFkB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer's disease. A cautionary note regarding C3aR. Front. Immunol. 6: 220.
29. Gregory, A. D., and A. M. Houghton. 2011. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res. 71: 2411-2416.
30. Souto, J. C., L. Vila, and A. Brú . 2011. Polymorphonuclear neutrophils and cancer: intense and sustained neutrophilia as a treatment against solid tumors. Med. Res. Rev. 31: 311-363.
31. Granot, Z., E. Henke, E. A. Comen, T. A. King, L. Norton, and R. Benezra. 2011. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 20: 300-314.
32. Fridlender, Z. G., J. Sun, I. Mishalian, S. Singhal, G. Cheng, V. Kapoor, W. Horng, G. Fridlender, R. Bayuh, G. S. Worthen, and S. M. Albelda. 2012. Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PLoS One 7: e31524.
33. Mishalian, I., R. Bayuh, L. Levy, L. Zolotarov, J. Michaeli, and Z. G. Fridlender. 2013. Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. Cancer Immunol. Immunother. 62: 1745-1756.
34. Eruslanov, E. B., P. S. Bhojnagarwala, J. G. Quatromoni, T. L. Stephen, A. Ranganathan, C. Deshpande, T. Akimova, A. Vachani, L. Litzky, W. W. Hancock, et al. 2014. Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J. Clin. Invest. 124: 5466-5480.
35. Niwa, Y., H. Akamatsu, H. Niwa, H. Sumi, Y. Ozaki, and A. Abe. 2001. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin. Cancer Res. 7: 285-289.
36. Moran, C. J., D. A. Arenberg, C. C. Huang, T. J. Giordano, D. G. Thomas, D. E. Misek, G. Chen, M. D. Iannettoni, M. B. Orringer, S. Hanash, and D. G. Beer. 2002. RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin. Cancer Res. 8: 3803-3812.
37. Jöhrer, K., L. Pleyer, A. Olivier, E. Maizner, C. Zelle-Rieser, and R. Greil. 2008. Tumour-immune cell interactions modulated by chemokines. Expert Opin. Biol. Ther. 8: 269-290.
38. Hong, M., A. L. Puaux, C. Huang, L. Loumagne, C. Tow, C. Mackay, M. Kato, A. Prévost-Blondel, M. F. Avril, A. Nardin, and J. P. Abastado. 2011. Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res. 71: 6997-7009.
39. Bugl, S., S. Wirths, M. P. Radsak, H. Schild, P. Stein, M. C. André, M. R. Muller, E. Malenke, T. Wiesner, M. Märklin, et al. 2013. Steady-state neutrophil homeostasis is dependent on TLR4/TRIF signaling. Blood 121: 723-733.
40. Medina-Echeverz, J., J. Fioravanti, M. Zabala, N. Ardaiz, J. Prieto, and P. Berraondo. 2011. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J. Immunol. 186: 807-815.
41. Ye, J., R. S. Livergood, and G. Peng. 2013. The role and regulation of human Th17 cells in tumor immunity. Am. J. Pathol. 182: 10-20.
42. + T cells. Immunity 22: 371-383.
43. Kim, H. J., and H. Cantor. 2014. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol. Res. 2: 91-98.
44. Mattes, J., M. Hulett, W. Xie, S. Hogan, M. E. Rothenberg, P. Foster, and C. Parish. 2003. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J. Exp. Med. 197: 387-393.
45. + lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J. Immunol. 153: 5659-5673.
46. Lim, H., Y. U. Kim, S. M. Drouin, S. Mueller-Ortiz, K. Yun, E. Morschl, R. A. Wetsel, and Y. Chung. 2012. Negative regulation of pulmonary Th17 responses by C3a anaphylatoxin during allergic inflammation in mice. PLoS One 7: e52666.
47. Pelletier, M., L. Maggi, A. Micheletti, E. Lazzeri, N. Tamassia, C. Costantini, L. Cosmi, C. Lunardi, F. Annunziato, S. Romagnani, and M. A. Cassatella. 2010. Evidence for a cross-talk between human neutrophils and Th17 cells. Blood 115: 335-343.
48. Muranski, P., A. Boni, P. A. Antony, L. Cassard, K. R. Irvine, A. Kaiser, C. M. Paulos, D. C. Palmer, C. E. Touloukian, K. Ptak, et al. 2008. Tumorspecific Th17-polarized cells eradicate large established melanoma. Blood 112: 362-373.
49. Hemdan, N. Y. 2013. Anti-cancer versus cancer-promoting effects of the interleukin-17-producing T helper cells. Immunol. Lett. 149: 123-133.
50. Cho, M. S., R. Rupaimoole, H. J. Choi, K. Noh, J. Chen, Q. Hu, A. K. Sood, and V. Afshar-Kharghan. 2016. Complement component 3 is regulated by TWIST1 and mediates epithelial-mesenchymal transition. J. Immunol. 196: 1412-1418.
51. Surace, L., V. Lysenko, A. O. Fontana, V. Cecconi, H. Janssen, A. Bicvic, M. Okoniewski, M. Pruschy, R. Dummer, J. Neefjes, et al. 2015. Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response. Immunity 42: 767-777.